← All trials
NCT06962631
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 18, 2025
- Primary completion
- Aug 27, 2026
- Completion date
- Feb 27, 2027
- First posted
- May 8, 2025
- Last posted
- Jul 29, 2025
- Enrollment
- 31
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.Lead sponsor
- Hospital do CoracaoCollaborator
- Hcor Research InstituteOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.